TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AUPH

Aurinia Pharmaceuticals Inc - Common Shares

NASDAQ
$14.70
▼ $2.04 (-12.2%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Nov 2026
H $19.25L $14.36-3.8%
$19.25$18.27$17.3$16.32$15.34$14.36$14.7
RSI (14)
Intraday · 15-minStrong sell-45RSI 34DowntrendMACD Bearishfor day-trading context — not advice

Technical signal

Strong sell-60
RSI (14)30
oversold 30overbought 70
Trend
Downtrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
below
vs 200-day
below
Support
$14.63
Resistance
$17.58
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2026-02-20 → 2026-11-20

Strategy return
-22.4%
Buy & hold
+2.1%
Trades
14
Win rate
7%

$100,000.00 invested would be worth $77,582.27 (-22.4%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Aurinia Pharmaceuticals Inc.· Biotechnology

source: yahoo

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Sector
Healthcare
Industry
Biotechnology
Employees
128
Headquarters
Edmonton, Canada
www.auriniapharma.com ↗

Fundamentals

source: yahoo
Market cap
$1.97B
P/E
6.4
P/B
3.0
EPS
$2.28
Div yield
0.0%
Profit margin
97.7%
ROE
61.4%
Debt / Equity
0.09
Beta
1.34
52-week range
$13.52 – $19.25
52-week low · $13.5221% of rangehigh · $19.25

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive3↑ · 2↓ · 3–
  • Earnings Beat May Change The Case For Aurinia Pharmaceuticals Stock▲ Positive
    Simply Wall St. · 06 Nov 2026
  • RBC Raises Price Target on Aurinia Pharmaceuticals to $18 From $16, Keeps Sector Perform, Speculative Risk— Neutral
    MT Newswires · 02 Nov 2026
  • Aurinia Pharmaceuticals Q3 Earnings Flat, Revenue Rises; 2026 Revenue Outlook Raised▲ Positive
    MT Newswires · 30 Oct 2026
  • Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
▲ Positive
Zacks · 30 Oct 2026
  • Aurinia: Q3 Earnings Snapshot— Neutral
    Associated Press · 30 Oct 2026
  • Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress— Neutral
    Business Wire · 30 Oct 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.